Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
The role of dermal fibroblasts in autoimmune skin diseases
Fibroblasts are an important subset of mesenchymal cells in maintaining skin homeostasis and resisting harmful stimuli. Meanwhile, fibroblasts modulate immune cell function by secreting cytokines, thereby implicating their involvement in various dermatological conditions such as psoriasis, vitiligo, and atopic dermatitis. Recently, variations in the subtypes of fibroblasts and their expression profiles have been identified in these prevalent autoimmune skin diseases, implying that fibroblasts may exhibit distinct functionalities across different diseases. In this review, from the perspective of their fundamental functions ...
Source: Frontiers in Immunology - March 13, 2024 Category: Allergy & Immunology Source Type: research
Recommendations on Topical Therapeutics for Vitiligo in Young Patients
This consensus statement reports on the development of expert recommendations for treating vitiligo in pediatric, adolescent, and young adult patients in the US. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 13, 2024 Category: Dermatology Source Type: research
Presentation of vitiligo in a case of COVID ‐19 infection concomitant with receiving remdesivir
Key Clinical MessageThe occurrence of vitiligo following COVID-19 infection and vaccination is well-documented. The mitochondrial dysfunction of melanocytes in vitiligo and the potential impact of RDV on mitochondria raise concerns about RDV possibly causing vitiligo. (Source: Clinical Case Reports)
Source: Clinical Case Reports - March 12, 2024 Category: General Medicine Authors: Farideh Beyki,
Saba Hasanzadeh,
Fariba Ghalamkarpour Tags: CASE REPORT Source Type: research
Prosthetic resin nail improves quality of life in patients with retronychia in a single-center clinical trial
To the Editor: Retronychia, an inflammatory condition characterized by arrested nail growth and nail plate ingrowth into the proximal nail fold, may cause pain, and affects quality of life (QOL). Therapeutic options, including nail avulsion and topical/intralesional corticosteroids, are often unsatisfactory (no resolution with nail avulsion and topical corticosteroids in 66% and 100%, respectively, in a retrospective study1 of 25 patients), leaving dermatologists empty handed.1 Hair pieces and long-lasting makeup improve QOL for hair loss and vitiligo patients, respectively. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - March 12, 2024 Category: Dermatology Authors: Kaya L. Curtis, Jose W. Ricardo, Bilal Shaikh, Tracey C. Vlahovic, Shari R. Lipner Tags: Research letter Source Type: research
Thyroid autoimmunity in relation to HLA-DRB1 and HLA-DQB1 polymorphism in nonsegmental vitiligo: a cross-sectional-study
CONCLUSION: Our findings suggest that HLA-DQ polymorphisms influence TAI risk in subjects with NSV, although HLA does not completely explain the co-occurrence of these two diseases.PMID:38463584 | PMC:PMC10918139 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - March 11, 2024 Category: Research Authors: Abdellatif Bouayad Laila Benzekri Source Type: research
